XML 112 R54.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Quarterly Financial Data (Unaudited) (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2015
Quarterly Financial Information Disclosure [Abstract] |
Quarterly Financial Data (Unaudited) |
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2015 |  |  |  |  | (a) (b) |  | (c) (d) |  |
Product revenues, net | $ | 2,172.3 |  |  | $ | 2,198.6 |  |  | $ | 2,391.7 |  |  | $ | 2,425.9 |  |  | $ | 9,188.5 |
Unconsolidated joint business revenues | $ | 330.6 |  |  | $ | 337.5 |  |  | $ | 337.2 |  |  | $ | 333.9 |  |  | $ | 1,339.2 |
Other revenues | $ | 52.0 |  |  | $ | 55.6 |  |  | $ | 49.0 |  |  | $ | 79.5 |  |  | $ | 236.1 |
Total revenues | $ | 2,555.0 |  |  | $ | 2,591.6 |  |  | $ | 2,777.9 |  |  | $ | 2,839.3 |  |  | $ | 10,763.8 |
Gross profit (1) | $ | 2,242.6 |  |  | $ | 2,305.5 |  |  | $ | 2,467.9 |  |  | $ | 2,507.5 |  |  | $ | 9,523.4 |
Net income | $ | 820.2 |  |  | $ | 924.8 |  |  | $ | 1,019.5 |  |  | $ | 828.7 |  |  | $ | 3,593.2 |
Net income attributable to Biogen Inc. | $ | 822.5 |  |  | $ | 927.3 |  |  | $ | 965.6 |  |  | $ | 831.6 |  |  | $ | 3,547.0 |
Net income per share: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | $ | 3.50 |  |  | $ | 3.94 |  |  | $ | 4.16 |  |  | $ | 3.77 |  |  | $ | 15.38 |
Diluted earnings per share attributable to Biogen Inc. | $ | 3.49 |  |  | $ | 3.93 |  |  | $ | 4.15 |  |  | $ | 3.77 |  |  | $ | 15.34 |
Weighted-average shares used in calculating: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | 235.0 |  |  | 235.3 |  |  | 232.2 |  |  | 220.4 |  |  | 230.7 |
Diluted earnings per share attributable to Biogen Inc. | 235.6 |  |  | 235.7 |  |  | 232.6 |  |  | 220.8 |  |  | 231.2 |
(In millions, except per share amounts) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
2014 | (e) |  | (f) (g) |  | (f) |  | (f) |  |
Product revenues, net | $ | 1,742.8 |  |  | $ | 2,056.3 |  |  | $ | 2,117.3 |  |  | $ | 2,287.0 |  |  | $ | 8,203.4 |
Unconsolidated joint business revenues | $ | 296.9 |  |  | $ | 303.3 |  |  | $ | 290.7 |  |  | $ | 304.5 |  |  | $ | 1,195.4 |
Other revenues | $ | 90.1 |  |  | $ | 61.9 |  |  | $ | 103.4 |  |  | $ | 49.2 |  |  | $ | 304.5 |
Total revenues | $ | 2,129.8 |  |  | $ | 2,421.5 |  |  | $ | 2,511.4 |  |  | $ | 2,640.7 |  |  | $ | 9,703.3 |
Gross profit (1) | $ | 1,850.5 |  |  | $ | 2,129.6 |  |  | $ | 2,208.8 |  |  | $ | 2,343.4 |  |  | $ | 8,532.3 |
Net income | $ | 479.7 |  |  | $ | 723.1 |  |  | $ | 856.1 |  |  | $ | 882.6 |  |  | $ | 2,941.6 |
Net income attributable to Biogen Inc. | $ | 480.0 |  |  | $ | 714.5 |  |  | $ | 856.9 |  |  | $ | 883.5 |  |  | $ | 2,934.8 |
Net income per share: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | $ | 2.03 |  |  | $ | 3.02 |  |  | $ | 3.63 |  |  | $ | 3.75 |  |  | $ | 12.42 |
Diluted earnings per share attributable to Biogen Inc. | $ | 2.02 |  |  | $ | 3.01 |  |  | $ | 3.62 |  |  | $ | 3.74 |  |  | $ | 12.37 |
Weighted-average shares used in calculating: |  |  |  |  |  |  |  |  |
Basic earnings per share attributable to Biogen Inc. | 236.8 |  |  | 236.7 |  |  | 236.2 |  |  | 235.5 |  |  | 236.4 |
Diluted earnings per share attributable to Biogen Inc. | 237.8 |  |  | 237.4 |  |  | 237.0 |  |  | 236.3 |  |  | 237.2 |
(1) Gross profit is calculated as total revenues less cost of sales, excluding amortization of acquired intangible assets.
(a) | Net income and net income attributable to Biogen Inc., for the third quarter of 2015, include a pre-tax charge to research and development expense of $48.1 million recorded upon entering into the collaboration agreement with AGTC.
(b) | Net income attributable to Biogen Inc., for the third quarter of 2015, reflects the attribution of a $60.0 million charge to noncontrolling interests, net of tax, related to a milestone payment due Neurimmune upon the enrollment of the first patient in a Phase 3 trial for aducanumab.
(c) | Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include a pre-tax charge to research and development expense of $60.0 million recorded upon entering into the collaboration agreement with MTPC.
(d) | Net income and net income attributable to Biogen Inc., for the fourth quarter of 2015, include pre-tax restructuring charges totaling $93.4 million.
(e) | Net income and net income attributable to Biogen Inc., for the first quarter of 2014, include pre-tax charges to research and development expense of $117.7 million recorded upon entering into the collaboration agreement with Eisai.
(f) | Product revenues, net and total revenues for the second, third and fourth quarters of 2014 include net revenues related to ALPROLIX as commercial sales of ALPROLIX commenced in the second quarter of 2014. Product revenues, net and total revenues for the third and fourth quarters of 2014 include net revenues related to ELOCTATE and PLEGRIDY as commercial sales of ELOCTATE and PLEGRIDY commenced in the third quarter of 2014.
(g) | Product revenues, net and total revenues for the second quarter of 2014 include the recognition of $53.5 million of revenue previously deferred in Italy relating to the pricing agreement with AIFA.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialInformationDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the quarterly financial data in the annual financial statements. The disclosure includes financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income (loss) before extraordinary items and cumulative effect of a change in accounting principle and earnings per share data. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306 + Details
Name: | us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration